Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | GHSR | Q92847 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5754487 | 0.69 | — | — | |
| SCHEMBL20223372 | 0.69 | — | — | |
| SCHEMBL14602900 | 0.68 | GUCY1B2 (0.34) | CNR2 | |
| SCHEMBL4405551 | 0.63 | CNR1 (0.31) | CNR2 | |
| SCHEMBL10189375 | 0.61 | GHSR (0.33) | LMNAGHSRKMT2A | |
| SCHEMBL13757022 | 0.61 | MAPT (0.51) | MAPTNPSR1CNR2LMNATP53 | |
| SCHEMBL4407794 | 0.61 | SMN1; SMN2 (0.39) | LMNATP53NPC1RAB9A | |
| SCHEMBL18016459 | 0.60 | HRH4 (0.42) | — | |
| SCHEMBL19221412 | 0.59 | LMNA (0.57) | LMNAGHSRKMT2A | |
| SCHEMBL13665882 | 0.59 | MAOB (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097594-B2 | Macrolides and ketolides having antimicrobial activity | WOCKHARDT LTD. (IN) | 2012-01-17 | — | — | US | disclosed |
| US-20100152185-A1 | DIPHENYL SUBSTITUTED CYCLOALKANES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | CHU LIN | 2010-06-17 | — | — | US | disclosed |
| US-7629467-B2 | 5-lipoxygenase activating protein inhibitors; antiatherosclerotic, antiasthmatic, antiallergic, antiinflammatory and cytoprotective agents | MERCK & CO., INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20090247478-A1 | Novel macrolides and ketolides having antimicrobial activity | SINDKHEDKAR MILIND DATTATRAYA | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247478-A1 | Novel macrolides and ketolides having antimicrobial activity | CYP51A1, CASP12, LSS | MAPT 3708/4885NPSR1 4361/4885CNR2 4517/4885 |
| US-20100152185-A1 | DIPHENYL SUBSTITUTED CYCLOALKANES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | ALOX5, LTC4S, ALOX15 | MAPT 4768/4885NPSR1 1303/4885CNR2 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.